Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study). (LUST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02310061
Recruitment Status : Unknown
Verified September 2016 by Carmine Zoccali, Istituto di Fisiologia Clinica CNR.
Recruitment status was:  Recruiting
First Posted : December 5, 2014
Last Update Posted : September 9, 2016
Sponsor:
Collaborators:
Manhes Hospital, Fleury Mérogis
Saarland University
Centre Hospitalier Universitaire, Amiens
Renal Unit, University of Madrid
Universitatea de Medicina si Farmacie Iasi
Medical University of Silesia
Hospital Universitari de Bellvitge
Akdeniz University
King's College London
Central Hospital, Nancy, France
ALTIR Nancy
University Hospital, Strasbourg
Shaare Zedek Medical Center
University Medical Centre Maribor
IASIO Hospital – General Clinic of Kallithea
ASL Parma
University Hospital, Ioannina
Hannover Medical School
Wroclaw Medical University
C.T.M.R. Saint-Augustin
Hospital Ambroise Paré Paris
Centre Hospitalier F.H. Manhès
Azienda USL 12 Versilia
Aristotle University Of Thessaloniki
Information provided by (Responsible Party):
Carmine Zoccali, Istituto di Fisiologia Clinica CNR

Brief Summary:

Volume overload is a leading risk factor for death and cardiovascular events in end stage renal disease patients maintained on chronic dialysis, particularly in those with myocardial ischemia and heart failure which represent a substantial fraction of this population. Early identification of volume overload may prevent cardiovascular sequel in these patients but clinical signs of volume expansion are unsatisfactory to reliably identify patients at risk and to monitor them over time. On the other hand, however reliable, standard techniques for measuring extracellular or circulating (blood) volume do not convey information on fundamental heart function parameters that determine the individual haemodynamic tolerance to volume excess and the response to ultrafiltration, i.e. left ventricular (LV) filling pressure and LV function.

Extra-vascular lung water is critically dependent on these parameters and represents a proxy of both, circulating volume and LV filling pressure and function, and may therefore be a better criterion to identify patients at a higher risk of volume-dependent adverse clinical outcomes and to monitor the effect of therapy aimed at preventing these outcomes. A fast (< 5 min.), easy to learn, simple and non-expensive technique which measures extra-vascular lung water by using standard ultrasound (US) machines has been validated in dialysis patients. Whether systematic measurement of lung water by this technique may translate into better clinical outcomes in End Stage Renal Disease (ESRD) patients has never been tested.

The aim of this randomized clinical trial is that of testing a treatment policy guided by extra-vascular lung water measurements by ultrasound to prevent death, decompensated heart failure and myocardial infarction as well as progression of Left Ventricular Hypertrophy (LVH) and LV dysfunction and hospitalization in high risk dialysis patients with myocardial ischemia (a history of myocardial infarction with or without ST elevation or unstable angina, acute coronary syndrome documented by ECG recordings and cardiac troponins or stable angina pectoris with documented coronary artery disease by prior coronary angiography or ECG) or overt heart failure (NYHA class III-IV).


Condition or disease Intervention/treatment Phase
Kidney Failure, Chronic Procedure: Extra-vascular lung water measurements by ultrasound (LW-US) Other: Standard protocol of fluid management in hemodialysis Phase 3

  Hide Detailed Description

Detailed Description:

Randomization procedure: After enrollment, patients will be randomized in 2 groups: treatment and control. The randomization will be performed by centre, with a 1:1 allocation ratio, and it will be communicated by the coordinating centre in Reggio Calabria. An allocation concealment will be observed.

Warning: based on the principle "once randomized, always randomized", if a patient drops out the study he cannot simply be replaced by a new one. New patients must be randomized as well.

Validation of core lab data: The core data to be collected in the LUST project/subprojects should be validated by the following validation centres:

  • CORE LUST STUDY DATA Echocardiographic data and US-lung data: Dr. Rosa Sicari and Dr. Luna Gargani, CNR Institute of Clinical Physiology of Pisa, Italy (rosas@ifc.cnr.it).
  • ANCILLARY LUST PROJECTS Pulse Wave Velocity data (PWV): Prof. Gerard London, Service d'Hémodialyse, Hôpital F.H. Manhès, Fleury-Mérogis, France (glondon@club-internet.fr).

    24 Ambulatory Blood Pressure Monitoring (ABPM) data: Dr. Grzegorz Bilo, Istituto Auxologico Italiano of Milan, Italy (g.bilo@auxologico.it).

Preliminary training on US-B lines measurement is a pre-requisite for Nephrologists and Cardiologists of each participating centre. After training (Skype meeting) an online certification will be released to certify the level of expertise about US-B lines measurements of all LUST study nephrologists and cardiologists.

Each participant centre will upload pertinent studies (echocardiography, 24h ABPM and PWV data) into the LUST website and will timely receive a feedback by the validation centres, whenever needed.

US Lung Scan technique A standard (3.0-MHz) echocardiography probe can be used for this purpose. Examinations should be performed in the supine position. To detect lung water, both sides of the chest should be scanned both in the anterior and lateral part from the second to the fourth (on the right side to the fifth) intercostals spaces, at parasternal, mid clavea, anterio-axillar and mid-axillary lines, as previously described (Am J Cardiol 2004;93:1265-70). An US-B line is a hyperechoic, coherent US bundle at narrow basis going from the pleura to the limit of the screen. These extended lines (also called comets) arise from the pleural line and should be differentiated from short comets' artifacts that may exist in other regions. US-B lines starting from the pleural line can be either localized or scattered to the whole lung and be present either as isolated US-B lines or in groups (with a distance >7 mm between 2 extended comets). The sum of US-B lines produces a score reflecting the extent of LW accumulation. If you do not detect any US-B line, the score is 0.

The investigators warn you about fixed US-B lines, due not to lung water but to fibrosis or inflammatory processes. These comets should be registered but not counted as US-B lines. The cause that underlies these artefacts should be described.

In patients allocated to the active arm of the study, any decision about weight reduction will be taken by Nephrologists only on the basis of pre-dialysis US-scans. However, also post-dialysis US-B lines measurement must be performed and registered. In the active and in the control arm as well, US-scans will be performed by the local cardiologist in coincidence with the echocardiographic study. It is crucial for the purpose of this study that cardiologists keep nephrologists involved in the LUST study blinded with respect to the number of US-B lines of patients of the control group.

Timing

  • In patients allocated to the control and the active arms, US-B lines should be performed at baseline and at 6, 12 and 24 months by the local cardiologist, in a non-dialysis day either on a Thursday or on a Friday, depending on the dialysis schedule.
  • In patients allocated in the treatment arm, the application of US-B scans should be performed as follows:
  • In patients with less than 15 US-B lines, ultrafiltration (UF) will not be modified and the US-B lines monitoring will be performed by the nephrologist at monthly intervals;
  • In patients with more than 15 US-B lines (either at baseline or at any of the monthly US-B Lung scans) UF will be performed by scheduling longer and/or additional dialyses (see below). In these patients, monitoring of US pre-dialysis and post-dialysis -B lines will be repeated at least once a week, until the goal is achieved (see next section).
  • Furthermore, in patients in the active arm, pre- and post-dialysis US-lung scans can be repeated at discretion of the nephrologist, i.e. whenever he/she believes that it can be useful applying this technique for monitoring the volume status of the patient, for example in a patient with <15 US-B lines who subsequently manifests a rise in body weight or in a patient who develops hypotension or frank hypotensive episodes during dialysis .

In brief, in the treatment group, monitoring is scheduled once a week (before and after dialysis), or even more frequently if the nephrologist believes that a more frequent monitoring may be useful to track the desired UF goal. When the number of US-B lines falls below 15, the measurements will be repeated at monthly intervals.

Weight reduction in patients with more than 15 US-B lines

In patients randomized to the treatment arm and with a number of US-B lines >15, a decrease of dry weight is required to reduce lung water, according to the following scheme derived by a pilot study at the coordinating centre and at the Iasi Nephrology Unit:

  • 15-30 US-B lines: decrease dry weight by 300 g over the following week (about 100 g per session)
  • 31-40 US-B lines: decrease dry weight by 450 g over the following week (about 150 g per session)
  • > 40 US-B lines: decrease dry weight by 600 g over next week (about 200 g per session).

Attempts to lower dry weight according to the previous scheme should continue until the US-B lines goal (<15) is attained. If the patient does not tolerate attempts to decrease dry weight for 2 weeks (i.e. if he/she develops hypotension, cramps and other symptoms) extra haemodialysis sessions should be considered.

If the goal (<15 pre-dialysis US B-lines) is not achieved after 4-6 weeks, or in case the patient does not tolerate UF, drug treatment (carvedilol, ACEi, ARB) intensification or introduction should be considered.

Once the goal is achieved, it is recommended to confirm it by repeating the measurement of US-B lines at least once, for example before the following dialysis.

Warnings:

  • In patients in the active arm with initial pre-dialysis US-B lines <15 and in those who achieve this goal thanks to body fluids subtraction who develop cramps and/or symptoms of extracellular volume depletion (low dry weight) the decision of increasing dry weight should be accompanied by close US-B lines monitoring (i.e. every dialysis session until the patient stabilizes).
  • In patients with >15 pre-dialysis US-B lines who do not tolerate dry weight decrease due to hypotension and who are on hypotensive/cardioprotective drugs treatment (carvedilol/ACEi) the dose of these drugs should be down-titrated and stopped, if needed. These drugs in these patients should be always given after dialysis (before going to bed, at night) rather than pre-dialysis.

Clinical (pre-dialysis) evaluation of volume status In both groups (treatment and control group), a standard pre-dialysis clinical evaluation of volume status should be done, as it is recommended in good clinical practice. This evaluation should consider blood pressure and change of blood pressure over time, pedal edema, presence/absence of dyspnea, crackles on lung auscultation (see below), body weight gain inter-dialysis and body weight trajectory over time. In the active arm of the study these data should also be formally registered whenever US-B lines measurements are done. In the control group, evaluation of volume status needs to be formally registered only in coincidence of the echocardiographic studies.

The following scale will be used for the evaluation of Crackles :

  1. No crackles
  2. I am uncertain about the presence of fine crackles
  3. Definite fine crackles at lung bases
  4. Moderate crackles
  5. Bilateral, diffuse crackles

For clinical edema, the following scale will be used:

  1. No clinical edema
  2. Slight pitting (2 mm depth) with no visible distortion
  3. Somewhat deeper pit (4 mm) with no readily detectable distortion
  4. Noticeably deep pit (6 mm) with the dependent extremity full and swollen
  5. Very deep pit (8 mm) with the dependent extremity grossly distorted

Echocardiographic measurements In both the intervention and control arm, cardiologists involved in the LUST study will perform the echocardiographic measurements at baseline, 6, 12 and 24 months, in a non-dialysis day on a Thursday or on a Friday, depending on the dialysis schedule. These echocardiogram are "research echocardiograms". For this reason, it is fundamental to keep nephrologists blind about the results of these echocardiographic readings.

Nevertheless, nephrologists are allowed to consult a cardiologist (be him the LUST cardiologist or another one) for a "clinical echocardiogram" if and when clinical problems arise which demand the application of echocardiographic studies for diagnostic reasons or for monitoring any underlying cardiac problem.

Detailed information about standardization of echocardiographic study has been prepared by echocardiography validation laboratory (Dr. Rosa Sicari and Dr. Luna Gargani, IFC CNR, Pisa).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lung Water By Ultra-Sound Guided Treatment To Prevent Death and Cardiovascular Complications in High Risk End Stage Renal Disease Patients With Cardiomyopathy (Lust Study)
Study Start Date : November 2013
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : May 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Control arm
Standard protocol of fluid management in hemodialysis
Other: Standard protocol of fluid management in hemodialysis
The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.

Experimental: Active arm
Extra-vascular lung water measurements by ultrasound (LW-US)
Procedure: Extra-vascular lung water measurements by ultrasound (LW-US)
It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
Other Name: LW-US




Primary Outcome Measures :
  1. Cumulative incidence of the composite outcome "death, myocardial infarction, heart failure". [ Time Frame: All events occurred during 24 months of follow up will be assessed at 1 year and 2 years after the start of the study. For Time-to-Event analyses, we will consider the time from the first visit to the first occurrence of death, or MI or heart failure. ]

    Myocardial infarction and heart failure will be defined on the basis of international standard protocols.

    - The following figures we expect to occur in the two study arms:

    Active arm: 30% Control arm: 45%


  2. All-cause and cardiovascular hospitalization. [ Time Frame: All events occurred during 24 months of follow up will be assessed at 1 year and 2 years after the start of the study. For Time-to-Event analyses, we will consider the time from the first visit to the first occurrence of all-cause and CV hospitalization ]

    Hospitalization will be characterized on the basis of ICD9 codes.

    - The following figures we expect to occur in the two study arms:

    Active arm: 1.00 hospitalization/patientyear Control arm: 1.50 hospitalization/patientyear


  3. Left atrial volume [ Time Frame: Left atrial volume (LAV) will be measured by cardiologists at baseline, 6, 12 and 24 months ]

    Left atrial volume will be measured by Echocardiography.

    We expect the following changes in LAV between the two study arms:

    Active arm: -2±17 Control arm: 4±17


  4. Diastolic function. [ Time Frame: Diastolic function (E/E') will be measured by cardiologists at baseline, 6, 12 and 24 months ]

    Diastolic function will be assessed by Echocardiography.

    We expect the following changes in E/E' between the two study arms:

    Active arm: -2±6 Control arm: 0±6


  5. Left ventricular mass index (LVMI) [ Time Frame: LVMI will be measured by cardiologists at baseline, 6, 12 and 24 months ]

    LVMI will be measured by Echocardiography.

    We expect the following changes in LVMI between the two study arms:

    Active arm: - 2±11 Control arm: 3±11


  6. Left ventricular ejection fraction (LVEF) [ Time Frame: LVEF will be measured by cardiologists at baseline, 6, 12 and 24 months ]

    Left ventricular ejection fraction will be measured by Echocardiography.

    We expect the following changes in LVEF between the two study arms:

    Active arm: 3±9% Control arm: 0±9%




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Dialysis vintage > 3 months
  • A history of myocardial infarction with or without ST elevation or unstable angina, acute coronary syndrome, documented by ECG recordings and cardiac troponins, or stable angina pectoris with documented coronary artery disease by prior coronary angiography or ECG or dyspnoea class III-IV NYHA
  • Written consent to take part in the study

Exclusion Criteria:

  • Cancer or other advanced non cardiac disease or comorbidity (e.g. end-stage liver failure) imposing a very poor short-term prognosis
  • Active infections or relevant inter-current disease
  • Inadequate lung scanning and echocardiographic studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02310061


Contacts
Layout table for location contacts
Contact: Carmine Zoccali, Prof 0965 397002 carmine.zoccali@tin.it

Locations
Layout table for location information
France
C.T.M.R. Saint Augustin Recruiting
Bordeaux, France
Principal Investigator: Thomas Bachelet, Prof         
Hôpital Ambroise Paré (Assistance-Publique Hôpitaux de Paris) Recruiting
Boulogne Billancourt, France
Principal Investigator: Ziad Massy, Prof         
Hôpital F.H. Manhès Recruiting
Fleury-Mérogis, France
Principal Investigator: Gerard London, Prof         
ALTIR - INSERM CHU de Nancy Recruiting
Nancy, France
Principal Investigator: Marie-Jeanne Coudert-Krier, Dr         
University Hospital Strasbourg Recruiting
Strasbourg, France
Principal Investigator: Thierry Hannedouche, Prof         
Germany
Hannover Medical School Recruiting
Hannover, Germany
Principal Investigator: Faikah Gueler, Prof         
Saarland University Medical Centre Recruiting
Homburg/Saar, Germany
Principal Investigator: Danilo Fliser, Prof         
Greece
University Hospital of Ioannina Recruiting
Ioannina, Greece
Principal Investigator: Kostas Siamopoulos, Prof         
IASIO Hospital - General Clinic of Kallithea Recruiting
Kallithea, Athens, Greece
Principal Investigator: Ariasteidis Stavroulopoulos, Prof         
Aristotle University Recruiting
Thessaloniki, Greece
Principal Investigator: Pantelis Sarafidis, Prof         
Israel
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel
Principal Investigator: Itzchak Slotki, Prof         
Italy
Miulli General Hospital Recruiting
Acquaviva delle Fonti, Bari, Italy
Principal Investigator: Carlo Basile, Prof         
Istituto Auxologico Italiano Recruiting
Milano, MI, Italy, 20100
Principal Investigator: Grzegorz Bilo, MD         
CNR Institute of Clinical Physiology Recruiting
Pisa, PI, Italy, 56100
Sub-Investigator: Luna Gargani, MD         
Sub-Investigator: Rosa Sicari, MD         
Principal Investigator: Eugenio Picano, Prof         
CNR-IBIM Clinical Epidemiology of Renal Diseases and Hypertension Unit Recruiting
Reggio Calabria, RC, Italy, 89100
Principal Investigator: Francesca Mallamaci, MD         
Sub-Investigator: Davide Bolignano, MD         
Sub-Investigator: Giovanni Luigi Tripepi, PhD         
Hospital "S. Maria della Scaletta" Not yet recruiting
Imola, Italy
Principal Investigator: Marcora Mandreoli, Prof         
Ospedale "A. Manzoni" Recruiting
Lecco, Italy
Principal Investigator: Giuseppe Pontoriero, Dr.         
ASL Parma Recruiting
Parma, Italy
Principal Investigator: Enrico Fiaccadori, Prof         
ASL 12, Versilia Hospital Recruiting
Viareggio, Italy
Principal Investigator: Vincenzo Panichi, Prof         
Poland
Medical University of Silesia in Katowice Recruiting
Katowice, Poland
Principal Investigator: Andrzei Wiecek, Prof         
Medical University Recruiting
Wroclaw, Poland
Principal Investigator: Marian Klinger, Prof         
Romania
University Hospital 'Dr C.I. Parhon' Recruiting
Iasi, Romania
Principal Investigator: Adrian Covic, Prof         
Slovenia
University Clinical Centre Recruiting
Maribor, Slovenia
Principal Investigator: Robert Ekart, Prof         
Spain
Bellvitge's University Hispital Recruiting
Barcelona, Spain
Principal Investigator: Alberto Martinez-Castelao, Prof         
Principal Investigator: Joseph M Grinyo, Dr         
Fundaciòn Jiménez Dìaz Not yet recruiting
Madrid, Spain
Principal Investigator: Alberto Ortiz, Prof         
Sponsors and Collaborators
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Manhes Hospital, Fleury Mérogis
Saarland University
Centre Hospitalier Universitaire, Amiens
Renal Unit, University of Madrid
Universitatea de Medicina si Farmacie Iasi
Medical University of Silesia
Hospital Universitari de Bellvitge
Akdeniz University
King's College London
Central Hospital, Nancy, France
ALTIR Nancy
University Hospital, Strasbourg
Shaare Zedek Medical Center
University Medical Centre Maribor
IASIO Hospital – General Clinic of Kallithea
ASL Parma
University Hospital, Ioannina
Hannover Medical School
Wroclaw Medical University
C.T.M.R. Saint-Augustin
Hospital Ambroise Paré Paris
Centre Hospitalier F.H. Manhès
Azienda USL 12 Versilia
Aristotle University Of Thessaloniki
Investigators
Layout table for investigator information
Principal Investigator: Carmine Zoccali, Prof CNR-IBIM and Nephrology Unit, Reggio Calabria

Publications:

Layout table for additonal information
Responsible Party: Carmine Zoccali, MD, FASN, Professor of Nephrology (PG), Istituto di Fisiologia Clinica CNR
ClinicalTrials.gov Identifier: NCT02310061     History of Changes
Other Study ID Numbers: ERA-EDTA-01062012
First Posted: December 5, 2014    Key Record Dates
Last Update Posted: September 9, 2016
Last Verified: September 2016
Keywords provided by Carmine Zoccali, Istituto di Fisiologia Clinica CNR:
Dialysis
ESRD
lung congestion
heart failure
LW-US
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic